Cargando…

Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease

BACKGROUND: Accurate determination of the extrahepatic extent and intrahepatic distribution of disease is very important in patients with primary and metastatic liver disease for deciding whether a patient receives potentially curable surgery or palliative treatment. Our objective was to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuker, Russ A, Mesoloras, Geraldine, Gulec, Seza A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1939707/
https://www.ncbi.nlm.nih.gov/pubmed/17623095
http://dx.doi.org/10.1186/1477-7800-4-17
_version_ 1782134400141492224
author Kuker, Russ A
Mesoloras, Geraldine
Gulec, Seza A
author_facet Kuker, Russ A
Mesoloras, Geraldine
Gulec, Seza A
author_sort Kuker, Russ A
collection PubMed
description BACKGROUND: Accurate determination of the extrahepatic extent and intrahepatic distribution of disease is very important in patients with primary and metastatic liver disease for deciding whether a patient receives potentially curable surgery or palliative treatment. Our objective was to evaluate the efficacy of delayed phase FDG-PET/CT imaging in lesion detection and to define its clinical impact compared to triple-phase contrast enhanced CT (CECT). METHODS: 30 patients underwent delayed phase FDG-PET/CT imaging (90 min whole body scan followed by a delayed abdominal scan at 120 min). Maximum standard uptake values (SUVs) and SUV ratios between tumor and normal liver parenchyma (T/N) were evaluated. In addition, comparison was made to CECT obtained within 10 days of the FDG-PET/CT to evaluate for lesion concordance within individual liver segments (Couinaud designation). RESULTS: Sites of primary malignancies included: colorectal (19), breast (3), pancreas (2), lung (2), carcinoid (2), cholangiocarcinoma (1), and hepatocellular carcinoma (1). There was a significant increase in SUV value of liver lesions between early and delayed acquisition (P < 0.001). Although there was not a significant reduction in liver background activity between the two studies, there was a strong increase in T/N ratio (P < 0.001) allowing better lesion detection by visual inspection. New lesions were identified in 5 of the 30 patients, which were not appreciated on the early scan. Delayed phase FDG-PET/CT identified one lesion which was not present on the corresponding CECT. Delayed phase FDG-PET/CT revealed extrahepatic sites of metastases not appreciated on CECT in 6 patients. CONCLUSION: Delayed phase FDG-PET/CT protocol improved lesion detectability in primary and metastatic liver disease, revealing new lesions in 17% of the patients. Moreover, FDG-PET/CT identified extrahepatic disease not seen on CECT in 20% of the patients.
format Text
id pubmed-1939707
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-19397072007-08-03 Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease Kuker, Russ A Mesoloras, Geraldine Gulec, Seza A Int Semin Surg Oncol Research BACKGROUND: Accurate determination of the extrahepatic extent and intrahepatic distribution of disease is very important in patients with primary and metastatic liver disease for deciding whether a patient receives potentially curable surgery or palliative treatment. Our objective was to evaluate the efficacy of delayed phase FDG-PET/CT imaging in lesion detection and to define its clinical impact compared to triple-phase contrast enhanced CT (CECT). METHODS: 30 patients underwent delayed phase FDG-PET/CT imaging (90 min whole body scan followed by a delayed abdominal scan at 120 min). Maximum standard uptake values (SUVs) and SUV ratios between tumor and normal liver parenchyma (T/N) were evaluated. In addition, comparison was made to CECT obtained within 10 days of the FDG-PET/CT to evaluate for lesion concordance within individual liver segments (Couinaud designation). RESULTS: Sites of primary malignancies included: colorectal (19), breast (3), pancreas (2), lung (2), carcinoid (2), cholangiocarcinoma (1), and hepatocellular carcinoma (1). There was a significant increase in SUV value of liver lesions between early and delayed acquisition (P < 0.001). Although there was not a significant reduction in liver background activity between the two studies, there was a strong increase in T/N ratio (P < 0.001) allowing better lesion detection by visual inspection. New lesions were identified in 5 of the 30 patients, which were not appreciated on the early scan. Delayed phase FDG-PET/CT identified one lesion which was not present on the corresponding CECT. Delayed phase FDG-PET/CT revealed extrahepatic sites of metastases not appreciated on CECT in 6 patients. CONCLUSION: Delayed phase FDG-PET/CT protocol improved lesion detectability in primary and metastatic liver disease, revealing new lesions in 17% of the patients. Moreover, FDG-PET/CT identified extrahepatic disease not seen on CECT in 20% of the patients. BioMed Central 2007-07-10 /pmc/articles/PMC1939707/ /pubmed/17623095 http://dx.doi.org/10.1186/1477-7800-4-17 Text en Copyright © 2007 Kuker et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kuker, Russ A
Mesoloras, Geraldine
Gulec, Seza A
Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease
title Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease
title_full Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease
title_fullStr Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease
title_full_unstemmed Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease
title_short Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease
title_sort optimization of fdg-pet/ct imaging protocol for evaluation of patients with primary and metastatic liver disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1939707/
https://www.ncbi.nlm.nih.gov/pubmed/17623095
http://dx.doi.org/10.1186/1477-7800-4-17
work_keys_str_mv AT kukerrussa optimizationoffdgpetctimagingprotocolforevaluationofpatientswithprimaryandmetastaticliverdisease
AT mesolorasgeraldine optimizationoffdgpetctimagingprotocolforevaluationofpatientswithprimaryandmetastaticliverdisease
AT gulecsezaa optimizationoffdgpetctimagingprotocolforevaluationofpatientswithprimaryandmetastaticliverdisease